-
Mashup Score: 0Lisaftoclax (APG-2575): In CLL/SLL Treatment: Safety and Efficacy as Monotherapy or Combined with Acalabrutinib or Ri... - 1 year(s) ago
Lisaftoclax (APG-2575): In CLL/SLL Treatment: Safety and Efficacy as Monotherapy or Combined with Acalabrutinib or Rituximab Matthew Davids By Matthew Davids, MD, MMSc So this is a brand new drug called Lisaftoclax, which is a BCL-2 inhibitor. BCL-2 inhibitors have also been developed, of course, like Venetoclax in …
Source: oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Acalabrutinib (AVO): A Promising New Triplet Treatment Option for High-Risk CLL Patients Phase 2 Study Results Matthe... - 1 year(s) ago
Acalabrutinib (AVO): A Promising New Triplet Treatment Option for High-Risk CLL Patients Phase 2 Study Results Matthew Davids By Matthew Davids, MD, MMSc This is a phase 2 investigator initiated clinical trial of a triplet regimen for the frontline treatment of CLL (chronic lymphocytic leukemia). And the 3 drugs are…
Source: oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The Phase 2 study for Acalabrutinib + AVO are incredibly promising for the oncology community, particularly for high-risk CLL patients. @DrMDavids @DanaFarber @HarvardMed #AVO #ASH22 Watch and Share the Video Here: https://t.co/f7HdT2y4D3 https://t.co/O6EEdWQyw8
-
-
Mashup Score: 1Paper: Dysregulated Humoral and Cellular Response to Sars-Cov-2 Vaccination in Patients with MGUS and SMM - 1 year(s) ago
Oral and Poster Abstracts 652. Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster II Research, Translational Research, Plasma Cell Disorders, Diseases, immunology, Lymphoid Malignancies, Biological Processes, Technology and Procedures, Study Population, Human, omics technologies Yoshinobu Konishi, MD, PhD1,2*, Romanos…
Source: ash.confex.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Dysregulated Humoral and Cellular Response to Sars-Cov-2 Vaccination in Patients with MGUS and SMM [Dec 11, 2022, 6-8p] Konishi et al. @IreneGhobrial Abs 3184 #ASH22 https://t.co/JURrogtY9g #COVID19Vaccine #mmsm #IDonc #COVID19nCancer HT @CyclingDoctor cc @COVID19nCCC
-
-
Mashup Score: 0MDS Real-world Study [2023] Treatment Patterns and Survival USOncology - Ira Zackon MD - 1 year(s) ago
Treatment Patterns and Overall Survival (OS) Among Patients with Myelodysplastic Syndromes (MDS) Treated in the US Community Oncology Setting: A Real-World Retrospective Observational Study by: Ira Zackon, MD – USOncology Network So our study is a retrospective we call descriptive study, really looking at treatment …
Source: oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Ira Zackon, MD #MDS Real-world Study [2023] Treatment Patterns and Survival 👁️ https://t.co/CeIcbjT8I0 #ASH22 @TheUSONetwork @OntadaOncology @NYOHPC https://t.co/ki8sragkxe
-
-
Mashup Score: 0Allogeneic Hematopoietic Cell Transplantation: How Can the ASAP Trial Help Relapsed or Refractory AML? Johannes Schet... - 1 year(s) ago
Allogeneic Hematopoietic Cell Transplantation: How Can the ASAP Trial Help Relapsed or Refractory AML? Johannes Schetelig By Prof. Dr. med. Johannes Schetelig So I’m going to tell you about the ASAP trial. This was not a trial about a new compound. It was a trial about a strategy, how to bring patients to a transpla…
Source: oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Check out this informative video on Oncology Tube by Prof. Dr. med. Johannes Schetelig about the ASAP trial. @WWU_Muenster #AllogeneicHematopoieticCellTransplantation #AML #ASAP #ASH22 Watch and Share the Video Here: https://t.co/1cD9bu0YcJ https://t.co/NqCIFgZ3hZ
-
-
Mashup Score: 0Idecabtagene Vicleucel Shows Effectiveness and Safety in High-Risk Multiple Myeloma Patients Krina Patel MD - 1 year(s) ago
Idecabtagene Vicleucel Shows Effectiveness and Safety in High-Risk Multiple Myeloma Patients Krina Patel MD By Krina Patel, MD, MSc So this trial is looking at ide-cel, or Idecabtagene Vicleucel, which is a CAR T-cell against BCMA, and it’s already been FDA-approved in a relapse-refractory setting for multiple myelo…
Source: oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Dr. Krina Patel shares some exciting news about a new treatment for high-risk multiple myeloma patients, the safely and efficacy of idecabtagene vicleucel. @DrKrinaPatel @MDAndersonNews #MultipleMyeloma #KarMMa2 #ASH22 Watch and Share the Video Here: https://t.co/eVenVCgm6q https://t.co/DtjQn3jaEi
-
-
Mashup Score: 0Social Media and the Adolescent and Young Adult (AYA) Patient with Cancer - Current Hematologic Malignancy Reports - 1 year(s) ago
Over 70,000 adolescent and young adults (AYA) aged 15 to 39 years are diagnosed with cancer each year in the US. The National Cancer Institute (NCI) has identified AYA cancer patients as a unique population. The most common cancers in this age group include tumors typically seen in pediatric patients such as acute lymphoblastic leukemia (ALL) and brain tumors, as well as cancers more typically…
Source: SpringerLinkCategories: Hem/Oncs, Latest HeadlinesTweet-
@DrMiguelPerales @MDAndersonNews @DrHKantarjian @mkonople @Transplant_Doc @GBorthakur @DianeBodurka @BouthainaDabaja @NitinJainMD @KMirza @Anand_88_Patel @mtmdphd @BldCancerDoc @jaltmanmd @VivekSubbiah @PedsHemeDoc Thank you 🙏🏾 @DrMiguelPerales #ASH22 https://t.co/sOKL6R6hLi @EK_Drake https://t.co/Bbn7rUMjYz
-
-
Mashup Score: 0Odronextamab: Promising Results in Treating Relapsed/Refractory Follicular Lymphoma: Findings from Phase II Study ELM... - 1 year(s) ago
Odronextamab: Promising Results in Treating Relapsed/Refractory Follicular Lymphoma: Findings from Phase II Study ELM-2 Tae Min Kim MD By Tae Min Kim, MD, PhD Our clinical trial is using the CD20xCD3 bispecific antibody and a monoclonal antibody targeting the follicular lymphoma cells in the second line failure sett…
Source: oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
A recent Phase II study, ELM-2, has shown promising results for Odronextamab in treating relapsed/refractory follicular lymphoma. Prof. Tae Min Kim @HospitalSeoul #TaeMinKimMDPhD #Odronextamab #FollicularLymphoma #ASH22 Watch and Share the Video Here: https://t.co/R6zvILSHyS https://t.co/fiYhz0r7Q9
-
-
Mashup Score: 0REGN5458: A Trial for Relapsed/Refractory Multiple Myeloma a BCMAxCD3 Bispecific Antibody Naresh Bumma MD - 1 year(s) ago
REGN5458: A Trial for Relapsed/Refractory Multiple Myeloma a BCMAxCD3 Bispecific Antibody Naresh Bumma MD By Naresh Bumma, MD – Ohio State University – The James The current stage for multiple myeloma treatment has changed very drastically in the last few years, with drugs such as anti-CD38 antibodies (bispecific an…
Source: oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
⚗️ REGN5458 trial, a BCMAxCD3 bispecific antibody being studied for relapsed/refractory multiple myeloma. Naresh Bumma, MD, 🥼 is leading the charge in this promising research. @OSUCCC_James #MultipleMyeloma #ASH22 Watch and Share the Video Here: https://t.co/jY1LxwC8Ie https://t.co/JX67Oo8CGj
-
-
Mashup Score: 0Zanubrutinib Outperforms Ibrutinib in Treating Relapsed/Refractory CLL/SLL Mehrdad Mobasher MD - 1 year(s) ago
Zanubrutinib Outperforms Ibrutinib in Treating Relapsed/Refractory CLL/SLL Mehrdad Mobasher MD By Mehrdad Mobasher, MD, MPH The ALPINE study was a phase 3 clinical trial done in relapsed/refractory CLL and SLL (small lymphocytic leukemia). This is the final analysis of PFS of this study. This study now shows Zanubru…
Source: oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The ALPINE clinical trial found Zanubrutinib, a Bruton tyrosine kinase inhibitor, to be more effective than ibrutinib in treating relapsed/refractory CLL and SLL. Dr. Mobasher @BeiGeneGlobal #Zanubrutinib #CLL #SLL #ASH22 Watch and Share the Video Here: https://t.co/2XDHMsjjmC https://t.co/djQZKtx5oP
-
Lisaftoclax for CLL/SLL: Monotherapy, Acalabrutinib, or Rituximab? 🥼 Dr. Matthew Davids discusses the treatment of CLL/SLL with Lisaftoclax/APG-2575. 📺 Watch the video on @OncologyTube https://t.co/orYIHB2rwD @DrMDavids @DanaFarber @HarvardMed #Lisaftoclax #ASH22 https://t.co/EVAao6MPel